Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma

(2012) Michael D. Blough et al.   ANNALS OF NEUROLOGY

Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951

(2012) Lale Erdem-Eraslan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation

(2012) Robert B Jenkins et al.   NATURE GENETICS

Moving toward molecular classification of diffuse gliomas in adults

(2012) B. J. Theeler et al.   NEUROLOGY

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

(2011) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

(2011) Stephen Yip et al.   JOURNAL OF PATHOLOGY

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Altered Telomeres in Tumors with ATRX and DAXX Mutations

(2011) C. M. Heaphy et al.   SCIENCE

Distinct germ line polymorphisms underlie glioma morphologic heterogeneity

(2011) Robert B. Jenkins et al.   Cancer Genetics

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

(2010) Brock C. Christensen et al.   JNCI-Journal of the National Cancer Institute

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

(2010) M. Labussiere et al.   NEUROLOGY

The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas

(2010) Lee A. D. Cooper et al.   PLoS One

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402

(2008) Caterina Giannini et al.   BRAIN PATHOLOGY

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

(2008) Francois Ducray et al.   Molecular Cancer